Kiora Pharmaceuticals Inc (KPRX) USD0.01

Sell:$3.14Buy:$3.35No change

Prices delayed by at least 15 minutes
Sell:$3.14
Buy:$3.35
Change:No change
Prices delayed by at least 15 minutes
Sell:$3.14
Buy:$3.35
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Key people

Brian M. Strem
President, Chief Executive Officer, Director
Melissa Tosca
Chief Financial Officer
Eric J. Daniels
Chief Development Officer
Praveen Tyle
Independent Chairman of the Board
Aron Shapiro
Director
David A. Hollander
Independent Director
Erin Parsons
Independent Director
Carmine Stengone
Independent Director
Click to see more

Key facts

  • EPIC
    KPRX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US49721T5074
  • Market cap
    $9.36m
  • Employees
    12
  • Shares in issue
    3.00m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.